About US
Contact us
-
Gilead and Agenus sign cancer drug development dealGilead Sciences has partnered with US-based biotechnology company Agenus for the development and commercialisation of up to five immuno-oncology (I-O) treatments. Under the terms of the deal, Gilead2018/12/24
-
Irish authorities demand €1.6bn in back tax from PerrigoThe Irish tax authority Revenue Commissioners has issued a Notice of Amended Assessment (NoA) to Perrigo stating the company owes €1.64bn in tax from 2013 intellectual property sales by Elan Pharma, w2018/12/24
-
As immuno-oncology heads into 2019, one thing is clear: It’s good to be MerckWhen 2018 began, there was still plenty of uncertainty surrounding the previously untreated lung cancer market—the holy grail for immuno-oncology drugmakers, thanks to its sheer size. Merck had the l2018/12/21
-
Talc lawyer says J&J's multibillion-dollar stock woes make settling look like a better dealWhat's bad for Johnson & Johnson shares is good for the trial lawyer leading the charge in the talc liability litigation—or so the lawyer says, as J&J scrambles to contain the damage from a bo2018/12/21
-
Attend the FierceBiotech Executive Breakfast at JP MorganShares of Eli Lilly were up nearly 3% in premarket trading on Wednesday after the company provided a revenue and profit forecast for next year that beat analysts’ expectations. Thenews, which was rele2018/12/20
-
GSK, Pfizer go for radical makeovers with giant consumer combo destined for spinoffTurns out, after GlaxoSmithKline walked away from a chance to scoop up Pfizer’s consumer health business in March, it got another opportunity to team up on a deal. The two Big Pharma companies have de2018/12/20
-
Lilly's Taltz beats out AbbVie's megadrug Humira in psoriatic arthritis showdownWhat’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis (PsA). Monday, the Indianapolis drugmaker said its anti-2018/12/19
-
Mallinckrodt spinoff to include 7 manufacturing sites in U.S. and JapanWith its plan for a spinoff into two companies, Mallinckrodt will create an API and generics operation with a large controlled substances and acetaminophen business and seven manufacturing facilities2018/12/19
-
Astellas buys Potenza Therapeutics for up to $405mJapanese pharmaceutical company Astellas Pharma has acquired US-based Potenza Therapeutics for a total consideration of up to $405m. The deal is made possible as Astellas exercised its option to buy2018/12/18
-
AbbVie licences BioArctic’s Parkinson’s disease portfolioSwedish biopharma company BioArctic has secured clearance from US Federal Trade Commission (FTC) to out-licence its alpha-synuclein antibody portfolio to AbbVie. The portfolio is intended for the tre2018/12/18